Drug Profile
UR 3216
Latest Information Update: 22 Jan 2008
Price :
$50
*
At a glance
- Originator Ube Industries
- Class Antiplatelets; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 14 Sep 1999 Preclinical development for Thrombosis in Japan (PO)